News Shionogi & Co., Ltd.

Stocks

4507

JP3347200002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:30:00 10/07/2026 BST			5-day change	1st Jan Change
2,832.50 ^JPY	-0.07%		-1.27%	-0.30%

07-11	Apnimed Files for US IPO to Support Sleep Apnea Drug Commercialization	MT
06-24	Shionogi Board Approves 568 Million Yen Treasury Share Disposal Under Restricted Stock Compensation Plan	MT

All News

Mentions Relevance

07-11	Apnimed Files for US IPO to Support Sleep Apnea Drug Commercialization	MT
06-24	Shionogi Board Approves 568 Million Yen Treasury Share Disposal Under Restricted Stock Compensation Plan	MT
06-19	Shionogi Announces Supplemental Approval For Pediatric Dosage And Administration Of XOCOVA To Treat COVID-19	CI
06-19	Shionogi Secures Approval for Pediatric Dosage of COVID-19 Drug Xocova in Japan	MT
06-18	Shionogi & Co., Ltd. Receives Approval For Additional Pediatric Dosage And Administration For Anti-Coronavirus Drug Zocova In Japan	CI
06-18	Shionogi & Co's New Antifungal Pill Shows Promising Results in Late-Stage Trial	MT
06-18	F2G Ltd and Shionogi Announces Positive Topline Results from Global Phase 3 Oasis Study Evaluating Oral Olorofim Versus Ambisome Followed by Standard of Care in Patients with Invasive Aspergillosis	CI
06-17	Shionogi & Co., Ltd. Achieves Primary Endpoint in Global Phase 3 Clinical Trial of Orolofim	CI
06-15	Goldman Sachs Upgrades Shionogi & Co to Buy from Neutral; Price Target is 3,400 Yen	MT
06-11	Dioseve, Inc. announced that it has received funding from Shionogi & Co., Ltd.	CI
06-05	Shionogi & Co Ltd Announces New Product Launch of 'ENDEAVORRIDE'	CI
06-01	US regulator approves oral drug from Japan's Shionogi to prevent COVID-19	RE
06-01	Shionogi & Co Secures US FDA Approval for Oral Antiviral to Prevent COVID-19 After Exposure	MT
06-01	Shionogi & Co., Ltd. Announces FDA Approval Of XOCOVA For Post-Exposure Prophylaxis Of COVID-19	CI
06-01	Shionogi Co Ltd - Shionogi's U.S. unit receives FDA approval for ensitrelvir as post-exposure prophylaxis for Covid-19	RE
05-31	Shionogi & Co., Ltd. Announces US FDA's Approval of the Anti-Coronavirus (SARS-CoV-2) Drug Encitrelvir Fumarate for Post-Exposure Prevention of Covid-19	CI
05-29	Shionogi & Co., Ltd.'s Group Company Shionogi China Co., Ltd. Receives Approval for Naldemedine for Opioid-Induced Constipation in China	CI
05-29	Shionogi Co: Shionogi China has received approval from NMPA of China for naldemedine, a treatment for opioid-induced constipation	RE
05-14	Shionogi Covid Pill Reduced Infection Risk in Late-Stage Study	MT
05-13	Shionogi & Co., Ltd. Announces Results from Its Global, Double-Blind, Randomized, Placebo-Controlled Phase 3 Study	CI
05-12	Shionogi : FY2025 Financial Results	PU
05-12	Shionogi : FY2025 Supplement	PU
05-12	Shionogi : FY2025 Financial Results	PU
05-12	Shionogi & Co., Ltd. Proposes Year End Dividend for the Year Ended March 31, 2026, Payable on June 25, 2026 and Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2027	CI
05-12	Shionogi & Co., Ltd. Provides Year-End Dividend Guidance for the Year Ending March 31, 2027	CI